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Aldosteronefacilitatescardiovasculardamagebyincreasingbloodpressureandthroughdiﬀerentmechanismsthatareindependent
of its eﬀects on blood pressure. In this respect, recent evidence involves aldosterone in the pathogenesis of metabolic syndrome.
Although this relationship is complex, there is some evidence suggesting that diﬀerent factors may play an important role, such
as insulin resistance, renin-angiotensin-aldosterone system, oxidative stress, sodium retention, increased sympathetic activity,
levels of free fatty acids, or inﬂammatory cytokines and adipokines. In addition to the classical pathway by which aldosterone
acts through the mineralocorticoid receptors leading to sodium retention, aldosterone also has other mechanisms that inﬂuence
cardiovascular tissue remodelling. Finally, overweight and obesity promote the adrenal secretion of aldosterone, increasing the
predisposition to type 2 diabetes mellitus. Further studies are needed to better establish therapeutic strategies that act on
the blockade of mineralocorticoid receptor in the treatment and prevention of cardiovascular diseases related to the excess of
aldosterone and the metabolic syndrome.
1.Introduction
Prevalence of hypertension and obesity is increasing around
the world, and data from NHANES III show that hyper-
tension increases parallel to a rising body mass index [1].
An increase in abdominal obesity, also when only moderate
overweight exits or even if there is no overweight, plays a
key role on cardiometabolic diseases [2]. This increase in
abdominal obesity is associated with carbohydrate and lipid
metabolism disorders and with elevation of blood pressure
levels. On the contrary, a rising subcutaneous adiposity does
not seem to be accompanied by any systemic complication
of obesity [3]. Most studies link abdominal obesity and
cardiometabolic disorders with the inﬂammatory status and
oxidative stress that lead to the development of insulin
resistance [4, 5]. Insulin resistance also plays a major role
in the development of metabolic syndrome and type 2 di-
abetes mellitus [6]. Moreover, hypertension usually occurs
at the same time with other risk factors: insulin resistance,
central obesity, dyslipidemia, and carbohydrate disorders, to
constitute the so-called cardiometabolic syndrome.
Aldosterone may lead to cardiovascular damage through
diﬀerent mechanisms that are independent on its hemody-
namic eﬀects on blood pressure. Thus, many recent stud-
ies involve aldosterone in the pathogenesis of the cardi-
ometabolic syndrome [7]; although this relationship is com-
plex and it is not well established, there is some evidence
thatdiﬀerentfactorscouldactonit:insulinresistance,renin-
angiotensin-aldosterone system, oxidative stress, sodium
retention and volume overload, increased sympathetic activ-
ity, levels of free fatty acids, or inﬂammatory cytokines
and adipokines. Renin-angiotensin-aldosterone system has
been linked with obesity-related hypertension [8], and it is
also involved in the association among obesity, metabolic
syndrome, dyslipidemia, insulin resistance, chronic kidney
disease,andhypertension[9].Theclassicalgenomicpathway
by which aldosterone acts through the mineralocorticoid
receptors are related to sodium retention and volume ex-
pansion. But, in addition, aldosterone has nongenomic
mechanisms too, acting on cardiovascular tissue remodeling
and on central nervous system, and then taking part in the2 International Journal of Hypertension
development of cardiometabolic syndrome, insulin resis-
tance and hypertension.
2. Genomicand Nongenomic Effects of
Aldosterone(Figure1)
The role of aldosterone on gene transcription and conse-
quently on the protein synthesis has been better known
since the introduction of molecular biology techniques [10].
Genomic mechanism of action of aldosterone has been
traditionally divided into two distinct phases [11–13]. In the
ﬁrst phase, an early (from 30 minutes onwards) activation
or inactivation of diﬀerent genes takes place; these genes can
modulate the activity of sodium and potassium transporters,
mainly the Na/K-ATPase, the sensitive to thiazides Na/Cl
cotransporter, and the epithelial sodium channel [14, 15].
Diﬀe r e n tp r o t e i n s ,s u c ha sS G K - 1 ,C H I F ,K i - R a s ,G I L Z ,o r
NDRG2, act in this phase [16–19]. By contrast, aldosterone,
in its later phase (from 3 hours), directly modulates the
expression levels of various sodium and potassium trans-
porters, leading to a net increase in sodium reabsorption and
potassium secretion.
Nevertheless, apart from the classical mechanisms men-
tioned above, aldosterone also has nongenomic or nonclassi-
cal eﬀects, which are independent on the mineralocorticoid
receptor and therefore are insensitive to the eﬀect of min-
eralocorticoid receptor antagonists such as spironolactone.
These nongenomic eﬀects of aldosterone (not requiring
signaling through the classical pathway including gene acti-
vation, transcription, and protein synthesis) were described
by Wehling et al. in 1992 [20]. These eﬀects take place
quickly (in seconds) and occur in various tissues from
both epithelial and nonepithelial origin, such as vascular
smooth muscle cells, endothelial cells, cardiac myocytes,
kidney cells, and colonic epithelial cells, as well as in cell
lines of human mononuclear leukocytes [21]. The nonge-
nomic eﬀects include: regulation of intracellular cations,
cell volume, redox status, metabolic signaling, and vascular
endothelium-dependentrelaxation[22].Inthelastyears,itis
becoming increasingly clear that these nongenomic and not
hemodynamic eﬀects of aldosterone constitute an important
part of the mechanisms by which aldosterone contributes
to the pathogenesis of metabolic syndrome and resistant
hypertension [22–24].
Elevated levels of aldosterone, in association with obesity
and insulin resistance, promote nongenomic inﬂammation
and oxidative stress, which advance the development of
resistanthypertensionthroughanumberofmechanisms[9].
In this way, it has been demonstrated that aldosterone can
inhibit the endothelium-dependent relaxation by decreasing
nitric oxide bioavailability (a consequence of increased re-
active oxygen species generation). In addition, perivascular
ﬁbrosis induced by aldosterone reduces vascular compliance
and increases arterial stiﬀness, and an increased Na/H
interchange stimulates vascular smooth muscle cell prolif-
eration [25, 26]. These actions potentiate the elevation of
blood pressure levels that occurs as consequence of classical
eﬀects of aldosterone (salt retention and volume expansion),
causing severe hypertension that is resistant to treatment
unless an appropriate mineralocorticoid receptor antagonist
(such as spironolactone or eplerenone) is used as part of the
therapeutic strategy.
3. Aldosterone and InsulinResistance
In the last years, we have learnt more about the actions
of aldosterone. At present, we know that it plays a role
in the pathogenesis of the metabolic syndrome [23]a n d
that elevated levels of aldosterone take part directly in the
pathogenesis of insulin resistance and endothelial dysfunc-
tion, facilitating a vascular remodeling that ultimately can
lead to resistant hypertension in association with obesity
and metabolic syndrome. The eﬀects of aldosterone on
cardiometabolic syndrome are independent on the action
of angiotensin II. Thus, in primary hyperaldosteronism,
where low plasma renin activity and angiotensin II levels
are found, there are higher levels of plasma glucose and
higher prevalence of cardiometabolic syndrome than in
essential hypertension [27]. Patients with primary hyper-
aldosteronism have more cardiovascular events than those
with essential hypertension [28].
Our group demonstrated that patients with primary
hyperaldosteronism have a greater intima-media thickness
and that it was related to plasma levels of aldosterone
and aldosterone/plasma renin activity ratio [29]. In addi-
tion, plasma levels of aldosterone are associated with car-
diometabolicsyndrome;Falloetal.[30]showedthatpatients
with primary hyperaldosteronism had higher levels of plas-
ma glucose and prevalence of cardiometabolic syndrome
than those with essential hypertension. Fallo et al. [31]
conﬁrmed that the excess of aldosterone has a negative eﬀect
on the glucose metabolism; this may explain at least in
part the higher number of cardiovascular events that we
can observe in primary hyperaldosteronism compared with
essential hypertension. In the same way, it is demonstrated
that there is an improvement in insulin resistance and
that plasma glucose and insulin levels decrease in patients
surgically treated of an aldosterone-producing tumor [32].
Similar results have been found with mineralocorticoid
receptor blockers in cases of idiopathic hyperaldosteronism.
Colussi et al. [33] performed a comparison between patients
with essential hypertension and normotensive subjects and
showed that a direct relationship exists between levels of
aldosterone and insulin resistance or hyperinsulinism; the
authorssuggestthatinhypertensivepatientsthisrelationship
maycontributebothtothepersistentelevatedbloodpressure
levels and to an increased cardiometabolic risk. Other two
large studies have also indicated that plasma levels of al-
dosterone but not renin are associated with metabolic
syndrome [34, 35].
However, Matrozova et al. [36] in their large series did
not ﬁnd diﬀerences in carbohydrate or lipid metabolism
between a group of 460 cases of primary hyperaldosteronism
and a control group of 1363 patients with essential hyper-
tension. Similar ﬁndings were obtained from the subanalysis
of the Trial of Preventing Hypertension Study [37], with
no evidence of higher levels of aldosterone in patients with
metabolic syndrome.International Journal of Hypertension 3
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The relationship between aldosterone and insulin re-
ported by diﬀerent studies is also supported by experimental
evidences; diﬀerent mechanisms by which aldosterone may
induce insulin resistance have been suggested: eﬀects of
hypokalaemiaonpancreaticbeta-cells,directeﬀectsofaldos-
terone on insulin receptors, activation of hepatic neogluco-
genesis, and eﬀects on Na/glucose cotransporter [38]. In
addition, it has been suggested that human adipocytes can
produce a mineralocorticoid releasing factor that promotes
the production of aldosterone [39]. Some data support that
aldosterone can have a negative eﬀect on the structure and
function of the pancreatic beta-cells, due to an increase in
inﬂammation and oxidative stress [23]a n dt oad e c r e a s e
in insulin sensitivity in human adipocytes [40]. It is also
possible that hyperinsulinemia may lead to higher levels of
aldosterone [41]; these higher levels of aldosterone may also
be related to the association between insulin resistance and
the amount of body fat. Fatty acids and adipokines have
an important role in the development of insulin resistance
[42] and both stimulate the production of aldosterone [43].
Experimental studies also show that adipocytes promote the
secretion of aldosterone in the adrenal glands [41].
4. Renin-Angiotensin-Aldosterone
Systemand Obesity
Upregulationof renin-angiotensin-aldosterone system,char-
acterized by higher levels of plasma renin activity and al-
dosterone, has been described in patients with visceral
obesity [44] ;t h i si m p r o v e sw h e np a t i e n t sl o s ew e i g h t[ 45].
This abnormal regulation of renin-angiotensin-aldosterone
system in obesity may result from a primary increase in
the production of renin-angiotensin-aldosterone system
components or may be the consequence of an alteration in
the atrial natriuretic peptide system [46].
The key role of renin-angiotensin-aldosterone system in
the regulation of systemic blood pressure and electrolyte ho-
meostasis has been well recognized for many years. In ad-
dition, in the last decade, its presence in a wide variety of
tissues has been described, such as adrenal glands, kidneys,
brain, heart, or blood vessels; this suggests the existence of a
local renin-angiotensin-aldosterone system that would act as
aregulatorofseveralfunctionsindiﬀerentorgans[42].Local
renin-angiotensin-aldosterone system has also been involved
in structural and functional pathologic changes that can take
place in diﬀerent organs, by modulating gene expression,
growth, ﬁbrosis, and possibly the inﬂammatory response
[43].
Recently, many data support the presence of a local
renin-angiotensin-aldosterone system in the adipose tissue
too, which may have an important role in the physiolog-
ical regulation of this tissue and may have also a role in
the pathophysiology of obesity and of obesity-related
hypertension. Several studies support this hypothesis. The
expression of angiotensinogen in human adipose tissue has
been demonstrated by studies with cultures of adipocytes
and preadipocytes [47]. The expression of angiotensinogen
seems to be regulated by free fatty acids, glucocorticoids,
and possibly by tumor necrosis factor-alpha [48]. However,
although the eﬀects of insulin in the hepatic expression of
angiotensinogen are well established, its role in the adipose
tissue is controversial.
It has been proven that production of angiotensin
II increases during the diﬀerentiation process of human
preadipocytes. Crandall et al. [49] identiﬁed angiotensin
II receptors in adipocytes, although the function of these
receptors is not established. Angiotensin II may also act on
other diﬀerent cell systems that we can ﬁnd in the adipose
tissue: endothelial cells, smooth muscle cells, sympathetic
nerve ﬁbers, lymphocytes, or mononuclear cells. We may
then hypothesize that angiotensin II released by adipocytes
could have a role in the physiology and pathophysiology
of the adipose tissue and even of other tissues closely
related to adipocytes. Several studies have found a direct4 International Journal of Hypertension
relationship between plasma levels of angiotensinogen and
body mass index in diﬀerent populations [50]. Plasma renin
activity and angiotensin-converting enzyme have also been
correlated positively with body mass index in obese patients
[50]. There is much evidence to suggest that angiotensin
II modulates the eﬀects of insulin [51]. Renin-angiotensin-
aldosterone system activation may inhibit the metabolic
eﬀects of insulin in the PI3 kinase pathway and at the same
time may facilitate its proliferative eﬀects via the MAP kinase
pathway [48]. Subjects with insulin resistance constitute
a high risk group of patients; some evidence supports a
therapeutic approach with AT1 receptor blockers in this
group of patients; in experimental models with increased
density of AT1 and AT2 receptors (what leads to the de-
velopment of hypertension and hyperinsulinemia), it has
been shown that these eﬀects may be avoided in the short
and longterm by blocking AT1 receptors [52]. Similarly,
in an experimental model of metabolic syndrome the
treatment with angiotensin-receptor blockers can inhibit
the development of hyperinsulinemia, hypertension, obesity,
heart hypertrophy, and atherosclerosis [51]. Some clinical
trials involving angiotensin-converting enzyme inhibitors
and angiotensin-receptor blockers showed an improvement
in carbohydrate metabolism in hypertensive subjects. Addi-
tionally, endothelial dysfunction (predictor of cardiovascular
morbimortality) may also be improved by blocking AT1
receptors [51]. Nevertheless, more studies are needed to con-
clude whether obesity and hypertension are both associated
with changes in the genetic expression of renin-angiotensin-
aldosterone system and to clarify the activity of renin-
angiotensin-aldosterone system on adipocytes [53].
Although some ﬁndings regarding renin-angiotensin-
aldosterone system in the adipose tissue may be controver-
sial, its implication in the physiology and pathophysiology of
this tissue has been conﬁrmed by several functional studies.
The inﬂuence of angiotensinogen in the development and
metabolism of the adipose tissue has been shown in diﬀerent
in vitro and in vivo studies. In vitro functional studies have
shown that adipocytes produce angiotensinogen and that a
risingadipositymayleadtoelevationofplasmareninactivity
[54]. In addition, levels of angiotensinogen and angiotensin
II are elevated in abdominal obesity [55]. Obesity, mainly
when associated to metabolic syndrome, is accompanied by
a raised sympathetic nervous system activity [46]. This fact
constitutes an important factor that increases renin secretion
in the kidneys. At the same time, angiotensin II increases
sympathetic nervous system activity. And both systems,
when activated, lead to an absence of inhibition of the heart
natriuretic peptides (which have important biological eﬀects
on plasma volume) [28].
4.1. Sympathetic Nervous System and RAAS. Hyperactivity
of the sympathetic nervous system plays a key role in the
development of diﬀerent metabolic disorders and hyperten-
sion in the cardiometabolic syndrome [56]. The presence
of visceral fat (more importantly than peripheral fat) may
constitute a major cause of this adrenergic enhancement;
the later would be more important in obese subjects than
in those with a normal weight, regardless of the presence
or absence of hypertension [57]. The augmented levels of
angiotensin II in obese patients have been related to the
activation of the sympathetic nervous system; however, the
physiologicalmechanismstoexplainthisrelationshiparenot
well established. It seems clear that in central obesity there
is an impaired function of baroreceptors and baroreﬂexes
and that this activates compensatory mechanisms to bring
back the adrenergic status, such as hyperinsulinism or in-
creased secretion of free fatty acids or leptin [58, 59]. Low
plasma levels of both grhelin and adiponectin lead to a
hyperstimulation of the sympathetic nervous system; the
infusion of both at the central nervous system in mice
reduces the activity of the sympathetic nervous system and
counteracts the positive eﬀects of leptin [60].
On the other hand, it has been hypothesized that aldos-
terone may be a nexus between adiposity and sympathetic
nervous system, since it has been shown that aldosterone
carries out central actions on adrenergic receptors in various
animal models [61]. Although angiotensin II contributes
signiﬁcantly to obesity-related hypertension, more studies
are needed to determine whether this is mediated by ac-
tivation of the sympathetic nervous system, by direct eﬀects
onthekidneysorbystimulating thesecretionofaldosterone.
In addition, central activation of mineralocorticoid re-
ceptor can modulate salt intake [62] and the onset of
hypertension mediated by the sympathetic nervous system
[63]. Recently, Kontac et al. [64], by applying intraneural
electrodes, demonstrated that there is a reversible sympa-
thetic hyperactivation in hypertensive patients with primary
hyperaldosteronism, which could accelerate target organ
damage in these subjects. An increase in plasma levels of
angiotensin II causes a hypothalamic neuronal activation (in
the supraoptic and paraventricular nuclei) and a vasopressor
eﬀect mediated by neural activation of the sympathetic
nervous system (through secretion of oubaoin) [65]. Central
blockade ofrenin-angiotensin-aldosterone systemcouldplay
a key role in reducing this proadrenergic status; in this
respect, it has been observed that the blockade of miner-
alocorticoid receptor in in vitro studies (by intraventricu-
lar brain infusion of an aldosterone-synthetase inhibitor)
restores the sympathetic hyperactivity and saline infusion-
related hypertension [66]. These and other studies support
the hypothesis that the activation of mineralocorticoid
receptor in the brain may increase sympathetic activity, at
least in part by activation of cerebral renin-angiotensin-
aldosterone system. Neurohormonal blockade of peripheral
eﬀects of aldosterone with appropriate blockers such as
spironolactone may diminish sympathetic activation in
hypertensive subjects [67] and patients with cardiometabolic
syndrome. This could lead to new therapeutic strategies
in patients with overactivation of nervous system and in
metabolic syndrome.
4.2. Interactions between Renin-Angiotensin-Aldosterone Sys-
tem and Adipose Tissue. Aldosterone inﬂuences insulin
metabolism through diﬀerent mechanisms in cardiovascular
and renal tissues, but also in adipose, muscle, and hepaticInternational Journal of Hypertension 5
tissues. It is well known that visceral fat produces inﬂamma-
torycytokines(adipokines)thattakepartinsystemicinﬂam-
mation, oxidative stress, and insulin resistance [4]. Some
studies suggest that mineralocorticoid receptor in adipocytes
facilitate the expression of inﬂammatory adipokines and
stimulate the proadipogenic eﬀect of aldosterone and gluco-
corticoids. In experimental studies, the inhibition of these
receptors reduces the expression of proinﬂammatory and
prothrombotic factors in the adipose tissue and increases the
heart and adipose tissue expression of adiponectin.
The adiponectin is a protein produced by the adipose
tissue that has beneﬁcial eﬀects on insulin resistance,
atherosclerosis, and inﬂammation. In humans, its levels
correlate indirectly with obesity, insulin resistance, diabetic
dyslipidemia, and hypertension [51]. This adipokine may be
the nexus between metabolic syndrome and cardiovascular
disorders. Fallo et al. [31] found lower levels of adiponectin
and a lower insulin sensitivity in primary hyperaldos-
teronism compared with hypertensive subjects with low
renin; a negative correlation was found between adiponectin
and insulin resistance HOMA index in both groups of
patients. A therapeutic approach based on correction of
adiponectin levels may improve the insulin sensitivity and
lead to a better vascular protection [68]. Furuhashi et al.
[69] demonstrated that the inhibition of renin-angiotensin-
aldosterone system by an angiotensin-converting enzyme
inhibitor or angiotensin-receptor blocker increases plasma
levels of adiponectin in hypertensive patients. Ronconi et
al. [70] found a higher incidence of metabolic syndrome in
primary hyperaldosteronism compared with essential hyper-
tension patients. They also analyzed two genetic adiponec-
tine polymorphisms that mark important diﬀerences in the
metabolic proﬁle of patients.
In addition, the human adipose tissue produces a miner-
alocorticoid releasing factor not yet identiﬁed that stimulates
the adrenal production of aldosterone and glucocorticoids
[71]. Both hormones interact on the mineralocorticoid
receptor increasing adipogenesis and macrophage inﬁltra-
tion, which are two important factors in the development of
inﬂammation in the adipose tissue. The interaction among
fat, adrenal cortex, and aldosterone/glucocorticoids may be
deﬁned as follows: a rising adiposity, mainly visceral adi-
posity, induces aldosterone and glucocorticoid production,
what in turn facilitates adipogenesis and inﬂammation of
the adipose tissue. A functional prorenin-renin receptor
has been described in human adipose tissue, with higher
expression levels in visceral than in subcutaneous fat [44].
This receptor may increase the local synthesis of angiotensin
II, leading to adipogenesis and adipocyte diﬀerentiation
[31, 72]. In vivo studies showed that patients with primary
hyperaldosteronism have low levels of adiponectin too,
and that it is associated to decreased insulin sensitivity
[72]. Losing weight decreases the levels of aldosterone and
improves insulin sensitivity both in subjects with normal
blood pressure and in hypertensive patients [73].
Finally, cardiovascular protective eﬀects of mineralo-
corticoid receptor blockers have been described [31, 73].
These protective eﬀects complement the eﬀects of renin-
angiotensin-aldosterone system blockade, although the risk
of hyperkalaemia when using in combination with angi-
otensin-convertinginhibitorsorangiotensinIIblockersmust
be considered. Then, the use of drugs from both groups
(blocking both systems at the same time) appears to be a
promising therapeutic strategy in the treatment of several
disorders, such as resistant hypertension, cardiovascular dis-
ease, or chronic nephropathy, although more clinical studies
are needed.
5. Aldosterone and Hypertension
There is a close relationship between aldosterone and hyper-
tension, so hypertension is always present when primary
hyperaldosteronism exists. In 1994 Gordon et al. [74]
suggested a high prevalence of primary hyperaldosteronism
when the aldosterone/plasma renin activity ratio was per-
formed as screening test in hypertensive patients previously
considered as cases of essential hypertension; this ﬁnding
supported primary hyperaldosteronism as the ﬁrst cause of
secondary hypertension. However, subsequent studies [75,
76] did not conﬁrm this high incidence and the suitability
of the ratio if no other studies are performed accompanying
the test. Beside the role of aldosterone in hypertension,
diﬀerentstudieshavealsoexaminedtherelationshipbetween
the mineralocorticoid receptor activation by steroids other
than aldosterone, mainly cortisol, and hypertension. In this
respect, we have previously described that cortisol is the
steroid that stimulates the mineralocorticoid receptor in
patients with Cushing’s syndrome through a mechanism
involving the saturation of the enzyme 11-hydroxysteroid
dehydrogenase; in this case, a positive eﬀect was observed
when plasma levels of cortisol were decreased using keto-
conazole; these mechanisms were also found to inﬂuence the
circadian blood pressure pattern in patients with Cushing’s
syndrome (loss of the normal day-night blood pressure
pattern) [77–79].
Aldosterone conducts its eﬀects through regulation of
blood volume and sodium transport. But in addition
aldosterone has proven to be involved in changes in the
nervous or cardiovascular systems that facilitate the devel-
opment of hypertension or cardiovascular diseases. Directly
or indirectly, aldosterone has inﬂuence on the eﬀects of
angiotensin II and consequently on the endothelium-
dependent vasorelaxation; this is associated to oxidative
stress on the vessel wall, leading to reduced availability of
nitric oxide. Treatment with spironolactone improves these
negativeeﬀects[80]. Aldosterone may play an important role
in the pathogenesis of cardiovascular diseases by releasing
reactive oxygen species, which could be independent on its
direct eﬀects on angiotensin II [22]. Some studies suggest
that oxidative stress may activate the mineralocorticoid
receptor [81]. Aldosterone is involved in vascular damage
and synthesis of collagen, facilitating arterial stiﬀness. Both
angiotensin II and aldosterone lead to proliferation and
vascular and cardiac remodelling, and both cardiomyocytes
and ﬁbroblasts express mineralocorticoid receptor with high
aﬃnity for aldosterone and glucocorticoids. Thus, aldos-
terone may contribute to an abnormal cardiac remodelling
mediated by ﬁbrosis and perivascular inﬂammation.6 International Journal of Hypertension
Many studies suggest that increased levels of aldosterone
in association with obesity and insulin resistance lead not
only to sodium retention and volume expansion but also to
inﬂammation and oxidative stress, what at the same time
facilitates the development of metabolic syndrome and resis-
tant hypertension [4]. Prevalence of resistant hypertension
in patients with primary hyperaldosteronism is 17–22%,
higher than in the general hypertensive population. These
data suggest a relationship between levels of aldosterone
and resistant hypertension. Besides, resistant hypertensive
patients without primary hyperaldosteronism have higher
levels of aldosterone and high volume expansion [82].
Elevated levels of aldosterone and cortisol in the 24-hour
urinesamplesuggestthatcorticotropinmayactasacommon
stimulus since this hormone can increase the levels of
aldosterone in patients with resistant hypertension [35].
Although the mechanisms by which increased cortisol and
aldosterone coexist in resistant hypertension are not well
established, some options have been suggested; for example,
the enhancement of the sympathetic activity could stimulate
both the secretion of aldosterone and cortisol [83]. It has
also been described diﬀerent factors secreted by adipocytes
that can increase adrenal secretion of aldosterone; these
factors may play a role as potential mediators in the obesity
and insulin resistance-related secretion of aldosterone and
cortisol [66, 84].
Aldosterone (both alone and in combination with
angiotensinII)promotesthedevelopmentofresistanthyper-
tension by producing adaptative changes in cardiovascular,
renal and nervous systems. Therefore, aldosterone induces
af a s ta n da d v e r s ee ﬀect on both vascular smooth muscle
and skeletal muscle and enhances the enzyme nicotinamide
adenine dinucleotide phosphate oxidase, leading to an excess
of reactive oxygen species, redox imbalance, and oxidative
stress [8].
In conclusion, the important role of aldosterone in the
pathogenesis of the metabolic syndrome, resistant hyper-
tension and cardiovascular diseases is increasingly evident.
Overweight and obesity favour the adrenal secretion of
aldosterone, what in turn is related to insulin resistance,
metabolic syndrome, and increased predisposition to type 2
diabetes mellitus. At present we know that the relationship
between renin-angiotensin-aldosterone system and insulin
resistance is inﬂuenced by complex mechanisms and that the
excess of aldosterone has negative eﬀects on carbohydrate
metabolism, hypertension, and kidney disorders. Never-
theless, further studies concerning aldosterone and insulin
resistance are needed to better establish potential therapeutic
strategies. Finally, there is some evidence that support an
important role of mineralocorticoid receptor blockers in the
treatment of resistant hypertension and in the prevention of
cardiovascular diseases in patients with metabolic syndrome
and type 2 diabetes mellitus.
References
[ 1 ]C .D .B r o w n ,M .H i g g i n s ,K .A .D o n a t oe ta l . ,“ B o d ym a s s
index and the prevalence of hypertension and dyslipidemia,”
Obesity Research, vol. 8, no. 9, pp. 605–619, 2000.
[ 2 ]K .G .A l b e r t i ,P .Z i m m e t ,a n dJ .S h a w ,“ T h em e t a b o l i cs y n -
drome—a new worldwide deﬁnition,” Lancet, vol. 366, no.
9491, pp. 1059–1062, 2005.
[3] D. B. Carr, K. M. Utzschneider, R. L. Hull et al., “Intra-
abdominal fat is a major determinant of the National Choles-
terolEducationProgramAdultTreatment PanelIIIcriteriafor
t h em e t a b o l i cs y n d r o m e , ”Diabetes, vol. 53, no. 8, pp. 2087–
2094, 2004.
[4] J. G. Neels and J. M. Olefsky, “Inﬂamed fat: what starts the
ﬁre?” Journal of Clinical Investigation, vol. 116, no. 1, pp. 33–
35, 2006.
[ 5 ]S .P .W e i s b e r g ,D .H u n t e r ,R .H u b e re ta l . ,“ C C R 2m o d u l a t e s
inﬂammatory and metabolic eﬀects of high-fat feeding,”
Journal of Clinical Investigation, vol. 116, no. 1, pp. 115–124,
2006.
[6] H. N. Ginsberg, “Insulin resistance and cardiovascular dis-
ease,” Journal of Clinical Investigation, vol. 106, no. 4, pp. 453–
458, 2000.
[7] S. Stas, A. T. Whaley-Connell, and J. R. Sowers, “Aldosterone
and hypertension in the cardiometabolic syndrome,” Journal
of Clinical Hypertension, vol. 10, no. 2, pp. 94–96, 2008.
[8] S. A. Cooper, A. Whaley-Connell, J. Habibi et al., “Renin-
angiotensin-aldosterone system and oxidative stress in cardio-
vascular insulin resistance,” American Journal of Physiology,
vol. 293, no. 4, pp. H2009–H2023, 2007.
[9] A. Whaley-Connell, M. S. Johnson, and J. R. Sowers, “Aldos-
terone: role in the cardiometabolic syndrome and resistant
hypertension,” Progress in Cardiovascular Diseases, vol. 52, no.
5, pp. 401–409, 2010.
[10] J. S. Williams and G. Williams, “50th anniversary of aldos-
terone,” Journal of Clinical Endocrinology and Metabolism, vol.
88, no. 6, pp. 2364–2372, 2003.
[11] F. Verrey, “Early aldosterone action: toward ﬁlling the gap
between transcription and transport,” American Journal of
Physiology, vol. 277, no. 3, pp. F319–F327, 1999.
[12] A. Bhargava and D. Pearce, “Mechanisms of mineralocorti-
coid action: determinants of receptor speciﬁcity and actions
of regulated gene products,” Trends in Endocrinology and
Metabolism, vol. 15, no. 4, pp. 147–153, 2004.
[13] M. Kellner, A. Peiter, M. Hafner et al., “Early aldosterone
up-regulated genes: new pathways for renal disease?” Kidney
International, vol. 64, no. 4, pp. 1199–1207, 2003.
[14] E. F´ eraille and A. Doucet, “Sodium-potassium-adenosin-
etriphosphatase-dependent sodium transport in the kidney:
hormonal control,” Physiological Reviews, vol. 81, no. 1, pp.
345–418, 2001.
[15] R. F. Reilly and D. H. Ellison, “Mammalian distal tubule:
physiology, pathophysiology, and molecular anatomy,” Phys-
iological Reviews, vol. 80, no. 1, pp. 277–313, 2000.
[16] N. Farman, S. Boulkroun, and N. Courtois-Coutry, “Sgk: an
old enzyme revisited,” Journal of Clinical Investigation, vol.
110, no. 9, pp. 1233–1234, 2002.
[17] H. Garty, M. Lindzen, R. Scanzano et al., “A functional
interaction between CHIF and Na-K-ATPase: implication for
regulation by FXYD proteins,” American Journal of Physiology,
vol. 283, no. 4, pp. F607–F615, 2002.
[ 1 8 ]O .G .M u l l e r ,R .G .P a r n o v a ,G .C e n t e n o ,B .C .R o s s i e r ,D .
Firsov, and J. D. Horisberger, “Mineralocorticoid eﬀects in
the kidney: correlation between alphaENaC, GILZ, and Sgk-
1 mRNA expression and urinary excretion of Na+ and K+,”
Journal of the American Society of Nephrology, vol. 14, no. 5,
pp. 1107–1115, 2003.
[19] S. Boulkroun, M. Fay, M. C. Zennaro et al., “Characterization
of rat NDRG2 (N-Myc downstream regulated gene 2), a novelInternational Journal of Hypertension 7
early mineralocorticoid-speciﬁc induced gene,” Journal of
Biological Chemistry, vol. 277, no. 35, pp. 31506–31515, 2002.
[20] M. Wehling, M. Christ, and K. Theisen, “Membrane recep-
tors for aldosterone: a novel pathway for mineralocorticoid
action,” American Journal of Physiology, vol. 263, no. 5, pp.
E974–E979, 1992.
[21] J. W. Funder, “The nongenomic actions of aldosterone,”
Endocrine Reviews, vol. 26, no. 3, pp. 313–321, 2005.
[22] E. L. Schiﬀrin, “Eﬀects of aldosterone on the vasculature,”
Hypertension, vol. 47, no. 3, pp. 312–318, 2006.
[23] J. R. Sowers, “Metabolic risk factors and renal disease,” Kidney
International, vol. 71, no. 8, pp. 719–720, 2007.
[24] N. J. Brown, “Aldosterone and vascular inﬂammation,” Hyper-
tension, vol. 51, no. 2, pp. 161–167, 2008.
[25] B. M. W. Schmidt, U. Sammer, I. Fleischmann, M. Schlaich,
C. Delles, and R. E. Schmieder, “Rapid nongenomic eﬀects of
aldosterone on the renal vasculature in humans,” Hyperten-
sion, vol. 47, no. 4, pp. 650–655, 2006.
[26] T. Y. Chun and J. Howard Pratt, “Nongenomic renal eﬀects
of aldosterone: dependency on NO and genomic actions,”
Hypertension, vol. 47, no. 4, pp. 636–637, 2006.
[27] C. Catena, R. Lapenna, S. Baroselli et al., “Insulin sensitivity
in patients with primary aldosteronism: a follow-up study,”
Journal of Clinical Endocrinology and Metabolism, vol. 91, no.
9, pp. 3457–3463, 2006.
[28] P. Milliez, X. Girerd, P.-F. Plouin, J. Blacher, M. E. Safar, and
J.-J. Mourad, “Evidence for an increased rate of cardiovascular
events in patients with primary aldosteronism,” Journal of the
American College of Cardiology, vol. 45, no. 8, pp. 1243–1248,
2005.
[29] P. Gonz´ alez-P´ erez and P. Stiefel, “Increased carotid intima-
media thickness in hypertensive patients with a high aldos-
terone/plasma renin activity ratio and elevated aldosterone
plasma concentration,” Journal of Hypertension, vol. 26, no. 7,
pp. 1499–1500, 2008.
[30] F. Fallo, F. Veglio, C. Bertello et al., “Prevalence and character-
istics of the metabolic syndrome in primary aldosteronism,”
Journal of Clinical Endocrinology and Metabolism, vol. 91, no.
2, pp. 454–459, 2006.
[31] F. Fallo, P. Della Mea, N. Sonino et al., “Adiponectin and
insulin sensitivity in primary aldosteronism,” American Jour-
nal of Hypertension, vol. 20, no. 8, pp. 855–861, 2007.
[32] G.Giacchetti,V.Ronconi,F.Turchietal.,“Aldosteroneasakey
mediator of the cardiometabolic syndrome in primary aldos-
teronism:anobservationalstudy,”JournalofHypertension,vol.
25, no. 1, pp. 177–186, 2007.
[33] G. Colussi, C. Catena, R. Lapenna, E. Nadalini, A. Chiuch,
and L. A. Sechi, “Insulin resistance and hyperinsulinemia are
related to plasma aldosterone levels in hypertensive patients,”
Diabetes Care, vol. 30, no. 9, pp. 2349–2354, 2007.
[34] M. Bochud, J. Nussberger, P. Bovet et al., “Plasma aldosterone
is independently associated with the metabolic syndrome,”
Hypertension, vol. 48, no. 2, pp. 239–245, 2006.
[35] S. Kidambi, J. M. Kotchen, C. E. Grim et al., “Association
of adrenal steroids with hypertension and the metabolic
syndrome in blacks,” Hypertension, vol. 49, no. 3, pp. 704–711,
2007.
[36] J. Matrozova, O. Steichen, L. Amar, S. Zacharieva, X. Jeune-
maitre, and P. F. Plouin, “Fasting plasma glucose and serum
lipids in patients with primary aldosteronism: a controlled
cross-sectional study,” Hypertension, vol. 53, no. 4, pp. 605–
610, 2009.
[37] B. M. Egan, V. Papademetriou, M. Woﬀord et al., “Metabolic
syndrome and insulin resistance in the TROPHY sub-study:
contrasting views in patients with high-normal blood pres-
sure,” American Journal of Hypertension, vol. 18, no. 1, pp. 3–
12, 2005.
[38] J. R. Sowers, A. Whaley-Connell, and M. Epstein, “Narrative
review: the emerging clinical implications of the role of aldos-
teroneinthemetabolicsyndromeandresistanthypertension,”
Annals of Internal Medicine, vol. 150, no. 11, pp. 776–783,
2009.
[39] M. Ehrhart-Bornstein, K. Arakelyan, A. W. Krug, W. A.
Scherbaum, and S. R. Bornstein, “Fat cells may be the obesity-
hypertension link: human adipogenic factors stimulate al-
dosterone secretion from adrenocortical cells,” Endocrine
Research, vol. 30, no. 4, pp. 865–870, 2004.
[40] D. Kraus, J. J¨ a g e r ,B .M e i e r ,M .F a s s h a u e r ,a n dJ .K l e i n ,
“Aldosterone inhibits uncoupling protein-1, induces insulin
resistance, and stimulates proinﬂammatory adipokines in
adipocytes,” Hormone and Metabolic Research, vol. 37, no. 7,
pp. 455–459, 2005.
[41] D. Petrasek, G. Jensen, M. Tuck, and N. Stern, “In vitro eﬀects
of insulin on aldosterone production in rat zona glomerulosa
cells,” Life Sciences, vol. 50, no. 23, pp. 1781–1787, 1992.
[42] V. J. Dzau, “Circulating versus local renin-angiotensin system
in cardiovascular homeostasis,” Circulation, vol. 77, 1, no. 6,
pp. I-4–I-13, 1988.
[43] . Min Ae Lee, M. Bohm, M. Paul, and D. Ganten, “Tissue
renin-angiotensin systems: their role in cardiovascular dis-
ease,” Circulation, vol. 87, 4, no. 5, pp. IV7–IV13, 1993.
[44] S. Engeli, R. Negrel, and A. M. Sharma, “Physiology and
pathophysiology of the adipose tissue renin-angiotensin sys-
tem,” Hypertension, vol. 35, no. 6, pp. 1270–1277, 2000.
[45] F. Fallo, G. Federspil, F. Veglio, and P. Mulatero, “The
metabolic syndrome in primary aldosteronism,” Current
Hypertension Reports, vol. 9, no. 2, pp. 106–111, 2007.
[46] R. Sarzani, F. Salvi, P. Dess` ı-Fulgheri, and A. Rappelli, “Renin-
angiotensin system, natriuretic peptides, obesity, metabolic
syndrome, and hypertension: an integrated view in humans,”
Journal of Hypertension, vol. 26, no. 5, pp. 831–843, 2008.
[47] S. Engeli, K. Gorzelniak, R. Kreutz, N. Runkel, A. Distler, and
A. M. Sharma, “Co-expression of renin-angiotensin system
genes in human adipose tissue,” Journal of Hypertension, vol.
17, no. 4, pp. 555–560, 1999.
[48] R. Cooper, N. McFarlane-Anderson, F. I. Bennett et al., “ACE,
angiotensinogen and obesity: a potential pathway leading to
hypertension,” Journal of Human Hypertension,v o l .1 1 ,n o .2 ,
pp. 107–111, 1997.
[49] D. L. Crandall, H. E. Herzlinger, B. D. Saunders, R. C.
Zolotor, L. Feliciano, and P. Cervoni, “Identiﬁcation and
characterization of angiotensin II receptors in rat epididymal
adipocyte membranes,” Metabolism, vol. 42, no. 4, pp. 511–
515, 1993.
[50] S.Umemura,N.Nyui,K.Tamuraetal.,“Plasmaangiotensino-
gen concentrations in obese patients,” American Journal of
Hypertension, vol. 10, no. 6, pp. 629–633, 1997.
[51] R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, “The metabolic
syndrome,” Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005.
[52] S. N. Iyer, M. K. Raizada, and M. J. Katovich, “AT1 receptor
density changes during development of hypertension in
hyperinsulinemic rats,” Clinical and Experimental Hyperten-
sion, vol. 18, no. 6, pp. 793–810, 1996.
[53] T. L. Goodfriend, D. L. Ball, B. M. Egan, W. B. Campbell,
and K. Nithipatikom, “Epoxy-keto derivative of linoleic acid
stimulates aldosterone secretion,” Hypertension,v o l .4 3 ,n o .2 ,
pp. 358–363, 2004.8 International Journal of Hypertension
[54] G. H. Goossens, E. E. Blaak, and M. A. Van Baak, “Possible
involvement of the adipose tissue renin-angiotensin system in
the pathophysiology of obesity and obesity-related disorders,”
Obesity Reviews, vol. 4, no. 1, pp. 43–55, 2003.
[55] S. Engeli, J. B¨ ohnke, K. Gorzelniak et al., “Weight loss and the
renin-angiotensin-aldosterone system,” Hypertension, vol. 45,
no. 3, pp. 356–362, 2005.
[56] J. Redon, R. Cifkova, S. Laurent et al., “Mechanisms of
hypertension in the cardiometabolic syndrome,” Journal of
Hypertension, vol. 27, no. 3, pp. 441–451, 2009.
[57] G. Grassi, R. Dell’Oro, A. Facchini, F. Q. Trevano, G. B. Bolla,
and G. Mancia, “Eﬀect of central and peripheral body fat
distribution on sympathetic and baroreﬂex function in obese
normotensives,” Journal of Hypertension, vol. 22, no. 12, pp.
2363–2369, 2004.
[58] G. E. Alvarez, S. D. Beske, T. P. Ballard, and K. P. Davy, “Sym-
pathetic neural activation in visceral obesity,” Circulation, vol.
106, no. 20, pp. 2533–2536, 2002.
[59] R. S. Ahima, “Adipose tissue as an endocrine organ,” Obesity,
vol. 14, supplement 5, pp. 242S–249S, 2006.
[60] A. A. da Silva, J. Carmo, J. Dubinion, and J. E. Hall, “The
role of the sympathetic nervous system in obesity-related
hypertension,” Current Hypertension Reports,v ol.11,no .3,pp .
206–211, 2009.
[61] E. P. Gomez-Sanchez, N. Ahmad, D. G. Romero, and C. E.
Gomez-Sanchez, “Is aldosterone synthesized within the rat
brain?” American Journal of Physiology, vol. 288, no. 2, pp.
E342–E346, 2005.
[62] A. F. De Nicola, C. Grillo, and S. Gonzalez, “Physiological,
biochemical and molecular mechanisms of salt appetite con-
trol by mineralocorticoid action in brain,” Brazilian Journal of
MedicalandBiologicalResearch,vol.25,no.12,pp.1153–1162,
1992.
[63] R. B. Felder, “Mineralocorticoid receptors, inﬂammation and
sympathetic drive in a rat model of systolic heart failure,”
Experimental Physiology, vol. 95, no. 1, pp. 19–25, 2010.
[64] A. C. Kontak, Z. Wang, D. Arbique et al., “Reversible
sympathetic overactivity in hypertensive patients with pri-
mary aldosteronism,” Journal of Clinical Endocrinology and
Metabolism, vol. 95, no. 10, pp. 4756–4761, 2010.
[65] B. S. Huang, S. Ahmadi, M. Ahmad, R. A. White, and F. H.
Leenen, “Central neuronal activation and pressor responses
induced by circulating ANG II: role of the brain aldosterone-
”ouabain” pathway,” American Journal of Physiology, vol. 299,
no. 2, pp. H422–H430, 2010.
[66] B. S. Huang, R. A. White, M. Ahmad, A. Y. Jeng, and F. H.
Leenen, “Central infusion of aldosterone synthase inhibitor
prevents sympathetic hyperactivity and hypertension by cen-
tralNainWistarrats,”AmericanJournalofPhysiology,vol.295,
no. 1, pp. R166–R172, 2008.
[67] M. Ehrhart-Bornstein, V. Lamounier-Zepter, A. Schraven et
al., “Human adipocytes secrete mineralocorticoid-releasing
factors,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 100, no. 2, pp. 14211–14216,
2003.
[68] T. W. Kurtz, “New treatment strategies for patients with
hypertension and insulin resistance,” American Journal of
Medicine, vol. 119, no. 5, supplement 5, pp. S24–S30, 2006.
[69] M. Furuhashi, N. Ura, K. Higashiura et al., “Blockade of
the renin-angiotensin system increases adiponectin concen-
trationsinpatientswithessentialhypertension,”Hypertension,
vol. 42, no. 1, pp. 76–81, 2003.
[70] V. Ronconi, F. Turchi, S. Rilli et al., “Metabolic syndrome in
primary aldosteronism and essential hypertension: relation-
ship to adiponectin gene variants,” Nutrition, Metabolism and
Cardiovascular Diseases, vol. 20, no. 2, pp. 93–100, 2010.
[71] C. Guo, V. Ricchiuti, B. Q. Lian et al., “Mineralocorti-
coid receptor blockade reverses obesity-related changes in
expression of adiponectin, peroxisome proliferator-activated
receptor-gamma, and proinﬂammatory adipokines,” Circula-
tion, vol. 117, no. 17, pp. 2253–2261, 2008.
[72] V. Lamounier-Zepter and M. Ehrhart-Bornstein, “Fat tissue
metabolism and adrenal steroid secretion,” Current Hyperten-
sion Reports, vol. 8, no. 1, pp. 30–34, 2006.
[73] M. L. Tuck, J. Sowers, and L. Dornfeld, “The eﬀect of
weight reduction on blood pressure, plasma renin activity,
and plasma aldosterone levels in obese patients,” New England
Journal of Medicine, vol. 304, no. 16, pp. 930–933, 1981.
[74] R. D. Gordon, M. Stowasser, T. J. Tunny, S. A. Klemm, and
J. C. Rutherford, “High incidence of primary aldosteronism
in 199 patients referred with hypertension,” Clinical and
Experimental Pharmacology and Physiology, vol. 21, no. 4, pp.
315–318, 1994.
[75] N. M. Kaplan, “The current epidemic of primary aldostero-
nism: causes and consequences,” Journal of Hypertension, vol.
22, no. 5, pp. 863–869, 2004.
[76] P. Stiefel, R. Aparicio, J. Carneado, E. Pamies, and J. Villar,
“The current epidemic of primary aldosteronism: causes and
consequences,” Journal of Hypertension, vol. 22, no. 10, pp.
2040–2042, 2004.
[77] P. Stiefel, J. S. Garc´ ıa-Morillo, L. Jimenez et al., “Role of keto-
conazole treatment in urinary-free cortisol-to-cortisone and
tetrahydrocortisol-to-tetrahydrocortisone ratios in nonec-
topic Cushing’s syndrome,” Endocrine, vol. 18, no. 3, pp. 279–
284, 2002.
[78] P. Stiefel and J. Carneado, “Cortisol, aldosterona y diferentes
formas de hipertensi´ on: papel de la 11-beta-hidroxiesteroide
dehidrogenasa,” Hipertensi´ on, vol. 17, no. 4, pp. 161–168,
2000.
[79] J. Gimenez, P. Stiefel, M. L. Miranda et al., “The dispersion
quotients: a new approach for evaluating the blood pressure
proﬁle in essential versus Cushing’s syndrome hypertensive
patients,” Annals of the New York Academy of Sciences, vol. 783,
pp. 321–323, 1996.
[80] K. K. Gaddam, M. K. Nishizaka, M. N. Pratt-Ubunama
et al., “Characterization of resistant hypertension: associa-
tion between resistant hypertension, aldosterone, and per-
sistent intravascular volume expansion,” Archives of Internal
Medicine, vol. 168, no. 11, pp. 1159–1164, 2008.
[81] G. E. Callera, R. M. Touyz, R. C. Tostes et al., “Aldosterone
activates vascular p38MAP kinase and NADPH oxidase via c-
Src,” Hypertension, vol. 45, no. 4, pp. 773–779, 2005.
[82] A. Prasad and A. A. Quyyumi, “Renin-angiotensin system and
angiotensin receptor blockers in the metabolic syndrome,”
Circulation, vol. 110, no. 11, pp. 1507–1512, 2004.
[83] H. Hitomi, H. Kiyomoto, A. Nishiyama et al., “Aldosterone
suppresses insulin signaling via the downregulation of insulin
receptor substrate-1 in vascular smooth muscle cells,” Hyper-
tension, vol. 50, no. 4, pp. 750–755, 2007.
[84] D. W. Wray and M. A. Supiano, “Impact of aldosterone
receptor blockade compared with thiazide therapy on sym-
pathetic nervous system function in geriatric hypertension,”
Hypertension, vol. 55, no. 5, pp. 1217–1223, 2010.